Greek pharma industry faces funding gap despite new measures

21 October 2024

The Greek pharmaceutical industry is grappling with severe underfunding, as recent government adjustments fall short of resolving a critical hospital drug financing gap.

New figures reveal that in the first half of 2023, pharmaceutical companies covered nearly 83% of the cost of hospital drugs priced over 30 euros ($32).

According to a recent statement by the Hellenic Association of Pharmaceutical Companies (SfEE), only 2.4 out of 10 hospital drugs were funded by the state in 2023, leaving the industry to absorb the remaining costs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical